This study evaluated the effectiveness and safety of TAS-102 (Lonsurf; trifluridine-tipiracil) plus Yttrium-90 (Y-90) radioembolization (RE) for patients with colorectal cancer liver metastasis (CRLM) who are unresponsive to chemotherapy. The data showed that TAS-102 plus RE was safe and effective in these patients.

This study evaluated the effectiveness and safety of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (Avastin) with or without atezolizumab (Tecentriq) on the outcomes of patients with metastatic (m) colorectal cancer (CRC). The study showed that adding atezolizumab to FOLFOXIRI plus bevacizumab regimen was safe and improved survival outcomes in these patients.

This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients.

This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine-tipiracil plus bevacizumab was safe and effective in patients with mCRC in a real-world setting.

This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these patients.

This study evaluated the effectiveness and safety of adding PolyPepI1018 peptide vaccine to fluoropyrimidine/bevacizumab (Avastin) maintenance therapy in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). The data showed that PolyPEPI1018 added to maintenance therapy was safe and associated with specific immune responses and antitumor activity in these patients.

This study compared the effectiveness and safety of immunotherapy versus standard treatment options in patients with metastatic colorectal cancer (mCRC). The data showed that immunotherapy tended to improve the survival outcomes in these patients.

This study evaluated the effectiveness and safety of bevacizumab (Avastin) plus TAS-102 (Lonsurf; trifluridine-tipiracil) versus TAS-102 alone for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab combined with TAS-102 was effective with manageable side effects in improving the outcomes of these patients.

This study investigated the effectiveness and safety of camrelizumab (SHR1210) in combination with XELOX (capecitabine and oxaliplatin) chemotherapy plus bevacizumab (Avastin) or regorafenib (Stivarga) as first-line therapy in patients with metastatic colorectal cancer (mCRC). The data showed that the combination was effective for these patients with manageable side effects.

This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients.